ACAD logo

ACADIA Pharmaceuticals Inc. (ACAD)

$18.67

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ACAD

Market cap

$3.23B

EPS

2.12

P/E ratio

8.9

Price to sales

2.99

Dividend yield

--

Beta

0.874159

Price on ACAD

Previous close

$18.75

Today's open

$18.84

Day's range

$18.59 - $19.44

52 week range

$15.86 - $30.96

Profile about ACAD

CEO

Catherine Owen Adams

Employees

798

Headquarters

San Diego, CA

Exchange

Nasdaq Global Select

Shares outstanding

172828972

Issue type

Common Stock

ACAD industries and sectors

Healthcare

Biotechnology & Life Sciences

News on ACAD

Acadia Pharmaceuticals Inc. (ACAD) Presents at UBS Global Biopharma Conference 2026 Transcript

Acadia Pharmaceuticals Inc. (ACAD) Presents at UBS Global Biopharma Conference 2026 Transcript

news source

Seeking Alpha • 4 hours ago

news preview

Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today presented additional data from the Phase 2 RADIANT trial evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP) during an oral presentation at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston. Building on previously announced topline results, new analyses provided further evidence of a consistent efficacy signal with once.

news source

Business Wire • 8 hours ago

news preview

Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in Japan

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced that it has entered into an exclusive distribution agreement with KYORIN Pharmaceutical Co., Ltd. (TSE: 4569), for the commercialization of DAYBUE® STIX (trofinetide) powder for oral solution in Japan for the treatment of Rett syndrome. Under the terms of the agreement, KYORIN will be responsible for leading the commercialization of DAYBUE STIX in Japan and the related regulatory activities on behalf of Acad.

news source

Business Wire • Nov 16, 2026

news preview

Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today reported that oral arguments were held before the U.S. Court of Appeals for the Federal Circuit in the appeal of the U.S. District Court for the District of Delaware's May 2025 decision upholding Acadia's U.S. Patent No. 11,452,721 (the ‘721 patent), which covers the NUPLAZID® (pimavanserin) 34 mg capsule formulation. “We continue to believe in the strength of our position on the NUPLAZID formulation patent, on which t.

news source

Business Wire • Nov 10, 2026

news preview

Acadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference

SAN DIEGO, Calif.--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present two data presentations related to Alzheimer's disease psychosis (ADP) and remlifanserin at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place November 16-19, 2026, in Boston. Acadia's presentations include an oral presentation featuring findings from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin in patients.

news source

Business Wire • Nov 9, 2026

news preview

Acadia Pharmaceuticals Inc. (ACAD) Q3 2026 Earnings Call Transcript

Acadia Pharmaceuticals Inc. (ACAD) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 5, 2026

news preview

What ACADIA Pharmaceuticals (ACAD) Said on Its Q3 Earnings Call

ACADIA Pharmaceuticals NASDAQ: ACAD reported third-quarter 2026 revenue of $342 million, up 22% from a year earlier on an adjusted basis, as demand for its Rett syndrome treatment DAYBUE and Parkinson's disease psychosis drug NUPLAZID drove growth.

news source

MarketBeat • Nov 5, 2026

news preview

Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2026. “Acadia delivered a strong third quarter, with total revenues of $342 million and continued commercial momentum across DAYBUE and NUPLAZID,” said Catherine Owen Adams, Chief Executive Officer of Acadia. “In the U.S., DAYBUE delivered another strong quarter, supported by meaningful uptake of DAYBUE STIX. In Europe, we are excited to build m.

news source

Business Wire • Nov 4, 2026

news preview

Acadia Pharmaceuticals (ACAD) Tops Q3 Earnings and Revenue Estimates

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.26 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

news source

PRNewsWire • Oct 29, 2026

news preview

¹ Disclosures

Get started with M1

Invest in ACADIA Pharmaceuticals Inc.

Open an M1 investment account to buy and sell ACADIA Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ACAD on M1